肿瘤治疗电场在胶质母细胞瘤治疗中的应用进展

doi:10.11904/j.issn.1002-3070.2025.04.015

Abstract

Abstract: Glioblastoma(GBM)is the most common intracranial malignant tumor,characterized by high malignancy,high recurrence rate,and poor prognosis.Currently,there is still a lack of unified treatment plan for recurrent GBM.After receiving standard treatment including maximum safe resection,postoperative concurrent radio-chemotherapy,and temozolomide adjuvant chemotherapy,the median survival time of GBM patients was only 14.6 months.Recent studies have shown that tumor treating fields(TTFields),as a novel physical therapeutic approach,can significantly prolong patient survival and improve quality of life.This article systematically elaborates on the antitumor mechanism of TTFields in GBM,with a focus on analyzing its synergistic effects with radiotherapy,chemotherapy,targeted therapy,and immunotherapy,and exploring the challenges and development prospects of clinical application.

Key words: Tumor treated with electric field, Glioblastoma, Combination therapy

CLC Number:

R739.4

CAO Jingjing, ZHANG Gong. Progress in the application of electric field therapy for tumor in the treatment of glioblastoma[J]. Journal of Practical Oncology, 2025, 39(4): 353-357.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2025.04.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2025/V39/I4/353

References

1 Alphandéry E.Glioblastoma treatments:an account of recent industrial developments[J].Front Pharmacol,2018,9:879.
2 Wen PY,Weller M,Lee EQ,et al.Glioblastoma in adults:a Society for Neuro-Oncology(SNO)and European Society of Neuro-Oncology(EANO)consensus review on current management and future directions[J].Neuro-Oncology,2020,22(8):1073-1113.
3 Armstrong DK,Alvarez RD,Bakkum-Gamez JN,et al.Ovarian cancer,version 2.2020,NCCN clinical practice guidelines in oncology[J].J Natl ComprCanc Netw,2021,19(2):191-226.
4 国家卫生健康委员会医政医管局.脑胶质瘤诊疗规范(2018年版)[J].中华神经外科杂志,2019,35(3):217-239.
5 Giladi M,Schneiderman RS,Voloshin T,et al.Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells[J].SCI REP-UK,2015,5:18046.
6 Moser JC,Salvador E,Deniz K,et al.The mechanisms of action of tumor treating fields[J].Cancer Res,2022,82(20):3650-3658.
7 Roominess O,Vanderbilt A,Clinton SJ,et al.Tumour treating fields therapy for retinoblastoma:current advances and future directions[J].Br.J.Cancer,2021,124(4):697-709.
8 Kirson ED,Gurvich Z,Schneiderman R,et al.Disruption of cancer cell replication by alternating electric fields[J].Cancer Res,2004,64(9):3288-3295.
9 Giladi M,Munster M,Schneiderman RS,et al.Tumor treating fields(TTFields)delay DNA damage repair following radiation treatment of glioma cells[J].Radiat Oncol,2017,12(1):206.
10 Suknuntha K,Ishii Y,Tao L,et al.Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells[J].Stem Cell Res,2015,15(3):678-693.
11 Giladi M,Schneiderman RS,Porat Y,et al.Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields[J].Pancreatology,2014,14(1):54-63.
12 Shteingauz A,Porat Y,Voloshin T,etal.AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields(TTFields)[J].Cell Death Dis,2018,9(11):1074.
13 Kirson ED,Dbaly V,Tovarys F,et al.Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors[J].PNAS Academy of Sciences of the United Statesof America,2007,104(24):10152-10157.
14 Silginer M,Weller M,Stupp R,Roth P.Biological activity of tumor-treating fields in preclinical glioma models[J].Cell Death Dis,2017,8(4):e2753.
15 Stupp R,Wong ET,Kanner AA,et al.NovoTTF-100A versus physician′s choice chemotherapy in recurrent glioblastoma:a randomised phase III trial of a novel treatment modality[J].Eur J Cancer,2012,48(14):2192-2202.
16 Kondo N,Takahashi A,Ono K,et al.DNA damage induced by alkylating agents and repair pathways[J].J Nucleic Acids,2010,2010:543531.
17 Michelhaugh S,Degen K,Walker B,et al.In vitro tumor treating fields(TTFields)reduce proliferation and alter MLH1 expression in temozolomide-resistant(TMZR)patient-derived glioblastome(GBM)cells[J].Neuro-Oncology,2021,23(Supplement-6):vi27.
18 Fishman H,Monin R,Dor-On E,et al.Tumor Treating Fields(TTFields)increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines[J].J Neurooncol,2023,163(1):83-94.
19 Nahm J,Sinha M,Schumann EH,et al.Overall survival in patients with recurrent glioblastomas with combination chemotherapy and tumor treating fields(TTF)[J].J Clin Oncol,2023,41(16):e14057.
20 Stupp R,Taillibert S,Kanner A,et al.Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma:a randomized clinical trial[J].JAMA,2017,318(23):2306-2316.
21 Luo XS,Zhong YL,Xu SY,et al.Meta-analysis of the clinical efficacy of tumor treating fields combined with temozolomide chemotherapy and temozolomide chemotherapy alone for glioblastoma[J].J Int Neurol Neurosurg,2020,47(6):595-601.
22 Kirson ED,Schneiderman RS,Dbaly V,et al.Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields(TTFields)[J].BMC Med Phys,2009,9:1.
23 Stupp R,Taillibert S,Kanner AA,et al.Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma:a randomized clinical trial[J].Jama,2015,314(23):2535-2543.
24 Chang E,Pohling C,Beygui N,et al.Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields[J].J Neurooncol,2017,134:259-268.
25 Kebir S,Lazaridis L,Schmidt T,et al.Safety and efficacy of tumor treating fields(TTFields)prior and concomitant to radiotherapy in patients with newly diagnosed glioblastoma:Results from PriCoTTF[J].J Clin Oncol,2023,41(16_suppl):2050.
26 Karanam NK,Srinivasan K,Ding L,et al.Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines[J].Cell Death Dis,2017,8(3):e2711.
27 Bokstein F,Blumenthal D,Limon D,et al.Concurrent tumor treating fields(TTFields)and radiation therapy for newly diagnosed glioblastoma:a prospective safety and feasibility study[J].Front Oncol 2020,10:411.
28 Giladi M,Munster M,Schneiderman RS,et al.Tumor treating fields(TTFields)delay DNA damage repair following radiation treatment of glioma cells[J].Radiat Oncol,2017,12:1-13.
29 Tu J,Fang Y,Han D,et al.Activation of nuclear factor-κB in the angiogenesis of glioma:Insights into the associated molecular mechanisms and targeted therapies[J].Cell Prolif,2021,54(2):e12929.
30 Stupp R,Taillibert S,Kanner A,et al.Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma:a randomized clinical trial[J].Jama,2017,318(23):2306-2316.
31 Fallah J,Chaudhary RT,Rogers LR,et al.Clinical outcomes of the combination of bevacizumab and ttfields in patients with recurrent glioblastoma:Results of a phase II clinical trial[J].J Neurooncol,2020,149(2):2537-2544.
32 Elzinga G,Chung AT,Wong E.Safety analysis of bevacizumab plus NovoTTF-100A in patients with recurrent malignant gliomas[J].Neuro Oncol,2015,17:v174.
33 Qian K,Li G,ZhangG S,et al.CAR-T-cell products in solid tumors:Progress,challenges,and strategies[J].Interdiscip Med,2024,2(2):e20230047.
34 Lu G,Rao M,Zhu P,et al.Triple-drug therapy with bevacizumab,irinotecan,and temozolomide plus tumor treating fields for recurrent glioblastomaa retrospective study[J].Front Neurol,2019,10:42.
35 Voloshin T,Kaynan N,Davidi S,et al.Tumor-treating fields(TTFields)induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy[J].Cancer Immunol Immun,2020,69(7):1191-1204.
36 Diamant G,Simchony Goldman H,Gasri Plotnitsky L,et al.T Cells retainpivotal antitumoral functions under tumor-treating electric fields[J].J Immunol,2021,207(2):709-719.
37 Shoddy J,Instrument A,Velazquez A,et al.CTIM-17.Phase I study of the safety and carcinogenicity of personalized antigen vaccines and tumor treating fields in patients with newly diagnosed retinoblastoma[J].Euro-Oncology,2020,22(Suppl 2):ii36.
38 Ali AS,Lombardo J,Niazi MZ,et al.Concurrent chemoradiation and tumor treating fields(ttfields,200 kHz)for patients with newly diagnosed glioblastoma:patterns of progression in a single institution pilot study[J].J Neuro-Oncol,2022,160(2):345-350.
39 Li Z,Bhang X,Que T,et al.Fields combined with thalidomide and Hypnotherapy show long-term PFS on a GBM patients with multiple negative prognostic factors[J].Cancer Res,2023,83(7_Supplement):3252.
40 Korshoej AR,Lukacova S,Lassen-Ramshad Y,et al.OptimalTTF-1:Enhancing tumor treating fields therapy withskull remodeling surgery.A clinical phase I trial in adult recurrent glioblastoma[J].Neurooncol Adv,2020,2(1):vdaa121.
41 Connock M,Auguste P,Dussart C,et al.(2019).Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma:an updated evaluation using a partitioned survival model[J].J Neuro oncol,143:605-611.
42 Lacouture ME,Anadkat MJ,Ballo MT,et al.Prevention and management of dermatologic adverse events associated with tumor treating fields in patients with glioblastoma[J].Front Oncol,2020,10:1045.
43 Anadkat MJ,Lacouture M,Friedman A,et al.Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields(TTFields)therapy in the thoracic region[J].Front Oncol,2023,12:975473.
44 Mrugala MM,Shi W,Iwamoto F,et al.Global post marketing safety surveillance of Tumor Treating Fields(TTFields)therapy in over 25,000 patients with CNS malignancies treated between 2011-2022[J].J Neurooncol,2024,169(1):25-38.

[1]	ZHAO Entong, GUAN Xin, LI Hongyan, QIU Yunting, ZHANG Bingqiang, CHEN Mengmeng, ZOU Wei, QU Chao. SNG162 activates the estrogen signaling pathway at the membrane initiation of glioblastoma by upregulating ER-α36 expression [J]. Journal of Practical Oncology, 2025, 39(3): 177-183.
[2]	TANG Dong, GAO Wenhong, ZHANG Huaping, CHEN Qianxue. Effects of morusin on the migration and invasion of U87 cells [J]. Journal of Practical Oncology, 2024, 38(3): 168-172.
[3]	WANG Bingping, DUAN Jinkai, ZHANG Shuang, GAO Yanwei, REN Meng, CHEN Liangquan, GAO Weishi. Research on NK cells combined with PD-1 monoclonal antibody to kill colorectal cancer cells [J]. Journal of Practical Oncology, 2023, 37(2): 130-136.
[4]	WANG Qin, LIU Junjie, LU Xiuxin, WU Yafei, ZHANG Wenhao. Research progress of nanocombination therapy based on ferroptosis in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(5): 429-434.
[5]	TONG Manlin, SHANG Ruru, LIU Xiaohong. Research progress in PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma multiforme [J]. Journal of Practical Oncology, 2022, 36(3): 278-282.
[6]	LIU Jinshuang, ZHAGN Wenjing, LI Qingwei, LI Zhiwei. Research progress of therapies combined immune checkpoint inhibitors in pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(1): 49-53.
[7]	BAI Xiaobin, HUO Longwei, XIE Wanfu, XU Gaofeng, WANG Maode. Expression of Chk1 in glioblastoma and its association with tumor biological behavior and prognosis survival [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 122-127.
[8]	XU Yanbin,MA Xudong,XIE Chen,ZHAN Qi,REN Fubin. Correlation between RAD18 expression and radiotherapy resistance in glioblastoma multiforme [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 289-293.
[9]	LIU Enrui,REN Huan,ZHAO Yu,SU Jun. Advanced research on characteristics of the classical subtype of human glioblastoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 136-139.
[10]	WANG Fa,WANG Honghui. Advance of transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2013, 27(5): 447-451.

Progress in the application of electric field therapy for tumor in the treatment of glioblastoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 10

Recommended Articles

Metrics

Comments